Clinical Trial Update: S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy [Phase 2]

View source ↗

Summary

A completed Phase 2 clinical trial (S0306) evaluating irinotecan in patients with recurrent or refractory advanced transitional cell cancer of the urothelium wh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Renal Pelvis
• Transitional Cell Carcinoma of the Ureter
• Urethral Cancer

Drugs mentioned

• Camptosar (irinotecan)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Status: COMPLETED